AOBase: a database for antisense oligonucleotides selection and design

Antisense oligonucleotides (ODNs) technology is one of the important approaches for the sequence-specific knockdown of gene expression. ODNs have been used as research tools in the post-genome era, as well as new types of therapeutic agents. Since finding effective target sites within RNA is a hard work for antisense ODNs design, various experimental methods and computational approaches have been proposed. For better sharing of the experimented and published ODNs, valid and invalid ODNs reported in literatures are screened, collected and stored in AOBase. Till now, ∼700 ODNs against 46 target mRNAs are contained in AOBase. Entries can be explored via TargetSearch and AOSearch web retrieval interfaces. AOBase can not only be useful in ODNs selection for gene function exploration, but also contribute to mining rules and developing algorithms for rational ODNs design. AOBase is freely accessible via .

[1]  Georg Sczakiel,et al.  Concepts to automate the theoretical design of effective antisense oligonucleotides , 2001, Bioinform..

[2]  Debora S. Marks,et al.  Antisense-Mediated Depletion Reveals Essential and Specific Functions of MicroRNAs in Drosophila Development , 2005, Cell.

[3]  Claes Wahlestedt,et al.  mRNA accessible site tagging (MAST): a novel high throughput method for selecting effective antisense oligonucleotides. , 2003, Nucleic acids research.

[4]  A. Dritschilo,et al.  Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. , 1993, Biochemical and biophysical research communications.

[5]  Xiaochen Bo,et al.  TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA. , 2005, Bioinformatics.

[6]  D. Prockop,et al.  Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA. , 1994, Biochemistry.

[7]  S. Crooke,et al.  An overview of progress in antisense therapeutics. , 1998, Antisense & nucleic acid drug development.

[8]  M. Byrom,et al.  Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis , 2005, Nucleic acids research.

[9]  Erik L. L. Sonnhammer,et al.  Computational antisense oligo prediction with a neural network model , 2002, Bioinform..

[10]  D. Ecker,et al.  Implication of RNA structure on antisense oligonucleotide hybridization kinetics. , 1992, Biochemistry.

[11]  S. Freier,et al.  Effects of RNA secondary structure on cellular antisense activity. , 2000, Nucleic acids research.

[12]  Michael C Giddings,et al.  Artificial neural network prediction of antisense oligodeoxynucleotide activity. , 2002, Nucleic acids research.

[13]  Pål Sætrom,et al.  Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming , 2004, Bioinform..

[14]  K. Flaherty,et al.  Antisense therapeutics: lessons from early clinical trials , 2001, Current opinion in oncology.

[15]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[16]  A D Tsodikov,et al.  Thermodynamic criteria for high hit rate antisense oligonucleotide design. , 2003, Nucleic acids research.

[17]  Olga V. Matveeva,et al.  ODNBase-a web database for antisense oligonucleotide effectiveness studies , 2000, Bioinform..

[18]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[19]  U. Zangemeister‐Wittke,et al.  Antisense therapy for cancer--the time of truth. , 2002, The Lancet. Oncology.

[20]  A D Tsodikov,et al.  Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. , 2000, Nucleic acids research.

[21]  Yedy Israel,et al.  Tetranucleotide GGGA Motif in Primary RNA Transcripts , 1998, The Journal of Biological Chemistry.

[22]  T. Smetsers,et al.  Bias in nucleotide composition of antisense oligonucleotides. , 1996, Antisense & nucleic acid drug development.

[23]  John J Rossi,et al.  Approaches for the sequence-specific knockdown of mRNA , 2003, Nature Biotechnology.

[24]  D. Prockop,et al.  Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides , 1994 .

[25]  Antonio J. Serrano,et al.  Profiled support vector machines for antisense oligonucleotide efficacy prediction , 2004, BMC Bioinformatics.

[26]  Sverdrup,et al.  Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination. , 1999, Drug discovery today.

[27]  E. Southern,et al.  Selecting optimal antisense reagents. , 2000, Advanced drug delivery reviews.

[28]  C. Lawrence,et al.  Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. , 2001, Nucleic acids research.

[29]  H. Allawi,et al.  Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase. , 2001, RNA.